Table 4 Factors associated with the occurrence of SMI loss.

From: Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma

Variable

OR (95%CI)

P-value

Pre-SBRT sarcopenia

0.24 (0.06–0.94)

0.04

BMI ≥ 24

0.48 (0.15–1.53)

0.21

Age (per 1-unit increase)

1.06 (1.01–1.12)

0.03

Sex female

26.70 (3.37–211.37)

0.002

ECOG ≥ 2

1.90 (0.42–8.63)

0.40

AFP ≥ 200 ng/ml

3.40 (0.90–12.88)

0.07

ALBI (per 0.01-unit increase)

1.020 (0.986–1.054)

0.25

Albumin (per 0.1-unit increase)

1.08 (0.76–1.52)

0.68

NLR (per 0.1-unit increase)

1.03 (1.00–1.05)

0.02

Child–Pugh A

3.43 (0.45–26.49)

0.24

Prior treatment

0.98 (0.32–3.02)

0.98

Multiple tumors

3.43 (0.99–11.90)

0.05

Tumor size ≥ 5 cm

6.32 (1.61–24.88)

0.008

Extrahepatic metastasis

0.87 (0.20–3.85)

0.86

Macrovascular invasion

1.80 (0.54–6.04)

0.34

BED (per 1 Gy increase)

0.999 (0.972–1.027)

0.96

  1. SMI: skeletal muscle index; SBRT: stereotactic body radiotherapy; BMI: body mass index; ECOG: Eastern Cooperative Oncology Group; AFP: alpha fetal protein; ALBI: albumin-bilirubin; NLR: neutrophil lymphocyte ratio; BED: biological effective dose; OR: odds ratio; CI: confidence interval.
Back to article page